Abstract:
System level priorities need to be implemented on cancer control and prevention as around 78% upsurge in new cancer cases are predicted by 2030 in Sri Lanka. One such priority is developing capacity of national health researchers to use genetic advancements in manipulating biologics for cancer treatment. The objective of this study is to highlight the clinical implications of establishment, development and effective Patient, Public Involvement and Engagement (PPIE) in a Cord Blood Bank (CBB), thereby, facilitating the use of genetically regulated Hematopoietic Stem Cells (HSCs) through Transcription Factor Mediated Differentiation System (TFMDS) derived from Umbilical Cord Blood (UCB) as a novel, state of the art approach in restoring post oncological patient immunity in Sri Lanka. Published literature in PubMed and Google-Scholar on the effect and impact of HSC, UCB, CBB and application of TFMDS genetic regulation in clinical oncology was analyzed. Analysis showed that application of TFMDS to RUNX1, FOSB, SPI1 transcription factors in HSC triggers formation of CD43+ cells contributing to enhanced immunity. Furthermore, UCB is an excellent source of HSC due to speedy availability and reduced incidence of graft versus host disease allowing transplantation of grafts with limited HLA disparity, extending donor pool. Authors suggest that establishment of a CBB and recruitment of UCB to obtain and administer genetically regulated HSCs through TFMDS as an effective clinical tool in boosting collapsed immunity in pediatric and geriatric post oncological patients. Remarkable stress is suggested on strategies to implement PPIE in this regard, allowing practicality in Sri Lankan context.
